These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16570004)

  • 1. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years.
    Kumar MS; Heifets M; Moritz MJ; Saeed MI; Khan SM; Fyfe B; Sustento-Riodeca N; Daniel JN; Kumar A
    Transplantation; 2006 Mar; 81(6):832-9. PubMed ID: 16570004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy.
    Anil Kumar MS; Heifets M; Fyfe B; Saaed MI; Moritz MJ; Parikh MH; Kumar A
    Transplantation; 2005 Sep; 80(6):807-14. PubMed ID: 16210969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
    Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
    Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
    Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
    Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.
    Le Meur Y; Thierry A; Glowacki F; Rerolle JP; Garrigue V; Ouali N; Heng AE; Delahousse M; Albano L; Lang P; Couzi L; Jaureguy M; Lebranchu Y; Mousson C; Glotz D; Kessler M; Vrtovsnik F; Rouanet S; Tagieva N; Kamar N
    Transplantation; 2011 Dec; 92(11):1244-51. PubMed ID: 22067312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab.
    Heilman RL; Reddy KS; Mazur MJ; Moss AA; Post DJ; Petrides S; Mulligan DC
    Transplant Proc; 2006 Jun; 38(5):1307-13. PubMed ID: 16797289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
    Heilman RL; Mazur MJ; Reddy KS; Moss A; Post D; Mulligan D
    Transplant Proc; 2005 May; 37(4):1785-8. PubMed ID: 15919466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
    Boswell A; Evans L; Rigg K; Shehata M
    Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
    Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
    Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results.
    Anil Kumar MS; Moritz MJ; Saaed MI; Heifets M; Sustento-Reodica N; Fyfe B; Kumar A
    Am J Transplant; 2005 Aug; 5(8):1976-85. PubMed ID: 15996248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of basiliximab induction therapy in ABO-incompatible kidney transplantation: a rapid steroid withdrawal protocol.
    Ando T; Tojimbara T; Sato S; Nakamura M; Kawase T; Kai K; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2004 Sep; 36(7):2182-3. PubMed ID: 15518793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.